Several distinct genetic alterations leading to METex14 have been reported but clinical significances of rare mutations are not well defined as well as outcomes of patients upon MET inhibitors (METi).<h4>Case presentation</h4>This report presents the case of a patient with metastatic NSCLC harboring an uncommon <i>MET</i> mutational landscape including notably a novel <i>MET</i>ex14 mutation (R1022L). This evidence concerns the gene MET and non-small cell lung carcinoma.